# Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/evaluation-of-efficacy-and-safety-of-the-glucagon-receptor-antagonist-ly2409021/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Christof Kazda,Ying Ding,Ronan P. Kelly,Parag Garhyan,Chunxue Shi,Chay Ngee Lim,Haoda Fu,David E. Watson,Andrew Lewin,William Landschulz,Mark A. Deeg,David E. Moller,Thomas A. Hardy |
| Citations | 218 |
| DOI | 10.2337/dc15-1643 |
| Fields | Medicine,Neuroscience |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://care.diabetesjournals.org/content/diacare/39/7/1241.full.pdf |
| OpenAlex ID | https://openalex.org/W2207556001 |
| PMID | 26681715 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Andrew Lewin](https://scholariq.org/researchers/andrew-lewin/)

## Paper journal

- [Diabetes Care](https://scholariq.org/journals/diabetes-care/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)
- [Neuropeptides and Animal Physiology](https://scholariq.org/topics/neuropeptides-and-animal-physiology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.